OncoMatch/Clinical Trials/NCT06177301

Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC

Is NCT06177301 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Tislelizumab combined with GX and Tislelizumab combined with GP for nasopharyngeal carcinoma.

Phase 3RecruitingFudan UniversityNCT06177301Data as of May 2026

Treatment: Tislelizumab combined with GX · Tislelizumab combined with GP — The study is being conducted to evaluate the safety and efficacy of tislelizumab combined with GX regimen versus tislelizumab combined with GP regimen in the first-line treatment of nasopharyngeal carcinoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Head and Neck Squamous Cell Carcinoma

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: PD-1 monoclonal antibody

Patients who had previously received PD-1 monoclonal antibody

Cannot have received: PD-L1 monoclonal antibody

Patients who had previously received ... PD-L1 monoclonal antibody

Cannot have received: CTLA4 monoclonal antibody

Patients who had previously received ... CTLA4 monoclonal antibody

Lab requirements

Blood counts

Hemoglobin (HB) ≥ 90g / L; Neutrophil count (ANC) ≥ 1.5 × 10^9 / L; platelets (PLT) ≥ 80 × 10^9 / L

Kidney function

Albumin ≥ 28g / L; Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance rate ≥ 60 ml / min

Liver function

Serum total bilirubin (BIL) ≤ 1.5 times the upper limit of normal (ULN); alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 2.5 × ULN; if liver metastasis, ALT and AST ≤ 5 × ULN

Blood routine examination: 1) Hemoglobin (HB)≥ 90g / L; 2) Neutrophil count (ANC) ≥ 1.5 × 10^9 / L; 3) platelets (PLT) ≥ 80 × 10^9 / L; Liver function: 1) Serum total bilirubin (BIL) ≤ 1.5 times the upper limit of normal (ULN); 2) alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 2.5 × ULN; if liver metastasis, ALT and AST ≤ 5 × ULN; Renal function: Albumin ≥ 28g / L; Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance rate ≥ 60 ml / min

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify